| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Eric Lefebvre last filed a Form 4 in January 2025, as Chief Medical Officer at PLRX. Eric Lefebvre's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Eric Lefebvre's trades have earned a strong insider score of 82/100 across 11 rated trades. Over a 12-month horizon, all 11 of those trades were profitable, with an average 12-month return of +50.4%.
At the last filing, the largest reported position was 240,224 shares of PLRX. The PLRX filings lean toward selling, a net 198,545 shares.
Eric Lefebvre has 20 Form 4 filings on record from December 2020 to January 2025, all as Chief Medical Officer at Pliant Therapeutics (PLRX), 2020–2025.
The 28 reported transactions were 16 open-market sales, 7 stock awards and 5 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 12 sales worth about $5.1M.
The largest open-market sale was 67,500 shares of PLRX at an average $34.48 on January 23, 2023, about $2.3M. Twelve months later PLRX was down 42%.
All 4 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
Shares as reported in the last Form 4 for each company; the most recent is from January 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 17, 2025 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 18,478 | $11.20 | $206,973.93 | -8.7% | -87.0% | -88.5% | |
| Jul 10, 2024 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 12,319 | $11.56 | $142,407.64 | -5.5% | +1.4% | -87.4% | |
| Jan 17, 2024 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 10,295 | $17.23 | $177,382.85 | -6.2% | -25.7% | -35.0% | |
| Jul 17, 2023 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 22,321 | $18.01 | $401,981.12 | -11.8% | -13.7% | -24.3% | |
| Mar 30, 2023 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell10b5-1 | 11,245 | $26.52 | $298,227.52 | -7.2% | -28.3% | -43.9% | |
| Jan 23, 2023 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell | 67,500 | $34.48 | $2,327,629.50 | -46.7% | +0.9% | -42.4% | |
| Dec 20, 2022 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell | 10,887 | $19.10 | $207,967.83 | -7.0% | +45.1% | -14.4% | |
| Oct 25, 2022 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell | 5,000 | $25.05 | $125,241.00 | -3.6% | +19.1% | -46.4% | |
| Jul 11, 2022 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell | 3,000 | $20.00 | $60,000.00 | -2.1% | -4.3% | -17.1% | |
| Jun 18, 2021 | PLRX Pliant Therapeutics, Inc. | Chief Medical Officer | Sell | 12,500 | $28.87 | $360,821.21 | -8.4% | -34.3% | -75.5% |